Back to Newsroom

Philadelphia Business Journal: Penn and PTC Therapeutics team up to research rare diseases

PTC Therapeutics Inc. has formed an orphan disease research collaboration with the Perelman School of Medicine at theUniversity of Pennsylvania.

The academic-industry partnership will focus on discovering and developing new treatments for rare diseases.

Stuart Peltz, CEO of PTC Therapeutics (NASDAQ: PTCT) in South Planfield, N.J., said their first project will be to look at Translarna as a potential treatment for Mucopolysaccharidosis-I, an inherited lysosomal storage disorder caused by a deficiency of an enzyme involved in the breakdown of complex carbohydrates.

Click here to read the full article